Combination therapy for portopulmonary hypertension with intravenous iloprost and oral bosentan

Research output: Contribution to journalCase reportContributedpeer-review



Severe portopulmonary hypertension (PPHTN) is a rare complication of liver cirrhosis and carries a poor prognosis. In the last years, intravenous (IV) epoprostenol has been suggested to be the optimal medical treatment for PPHTN, and recently oral bosentan has been shown to be efficacious and safe in selected patients with PPHTN. We report a case of PPHTN suffering from recurrent right heart failure while on treatment with IV iloprost, which was successfully managed by combination therapy with IV iloprost plus oral bosentan, providing sustained cardiopulmonary stabilization for at least two years. This report documents the first case of a patient with PPHTN successfully treated with the combination of IV iloprost and oral bosentan over an extended period. Thus, combination therapy with IV iloprost and oral bosentan might be a promising new option for selected patients suffering from PPHTN and recurrent right heart failure.


Original languageEnglish
Pages (from-to)376-80
Number of pages5
JournalWiener medizinische Wochenschrift : WMW ; international medical journal
Issue number15-16
Publication statusPublished - Aug 2005

External IDs

PubMed 16160926
Scopus 24744458364
ORCID /0000-0001-6022-6827/work/142659552



  • Administration, Oral, Adult, Antihypertensive Agents/administration & dosage, Bosentan, Drug Therapy, Combination, Follow-Up Studies, Heart Failure/etiology, Hemodynamics, Humans, Hypertension, Portal/complications, Hypertension, Pulmonary/complications, Iloprost/administration & dosage, Injections, Intravenous, Liver Cirrhosis, Alcoholic/complications, Male, Recurrence, Sulfonamides/administration & dosage, Time Factors